在没有心力衰竭诊断的情况下,用循环利尿剂治疗的患者的结果:一项回顾性队列研究
Joseph James Cuthbert1,2, Ireneous Soyiri3, Stephanie Jayne Lomax4
1Clinical Sciences Centre, Hull York Medical School, University of Hull, Hull, UK joe.cuthbert@hyms.ac.uk.
Heart (British Cardiac Society)
|April 17, 2024
概括
循环利尿剂经常被处方给没有心力衰竭 (HF) 诊断的患者. 这些患者经历HF事件的频率与被诊断的HF患者相似,这表明许多人可能患有未被诊断的心力衰竭.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 公共卫生 公共卫生
背景情况:
- 循环利尿剂通常在初级保健中被处方.
- 处方并不总是与记录的心力衰竭 (HF) 诊断相关联.
- 在没有记录HF诊断的患者中,HF事件的发生率尚不清楚.
研究的目的:
- 为了调查患者心力衰竭 (HF) 事件的发生率,在没有正式HF诊断的情况下,处方循环利尿剂.
- 将这些事件与诊断为HF的患者和高风险患者的事件进行比较.
主要方法:
- 一项倾向匹配的队列研究使用了英国的电子健康记录.
- 没有HF诊断的循环利尿剂患者与HF患者和HF风险组的患者进行了比较.
- 主要终点是HF事件的组合,包括症状,住院,诊断和全因死亡率.
主要成果:
- 在倾向匹配后,未诊断HF的循环利尿剂患者的HF事件发生率与诊断HF的患者相比相似 (71.9%vs72.1%).
- 没有HF诊断的循环利尿剂患者的HF事件发生率是HF风险组的两倍 (71.9%vs35.7%).
结论:
- 没有经过记录的HF诊断的患者处方循环利尿剂的患者经历HF事件的发生率与被诊断的HF患者相似.
- 处方循环利尿剂的大量患者可能患有未诊断的心力衰竭.
- 这凸显了接受循环利尿剂的患者需要仔细评估和诊断的必要性.
相关概念视频
Heart Failure Drugs: Diuretics
370
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
370
Antihypertensive Drugs: Potassium-Sparing Diuretics
531
Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
531
Antihypertensive Drugs: Action of Diuretics
679
Diuretics are antihypertensive drugs used to treat hypertension resulting from sodium and water retention. Sodium, vital for fluid balance and nerve or muscle function, is regulated by the kidneys through millions of nephrons. Blood enters nephrons via afferent arterioles, which branch into capillaries called glomeruli. These filter blood plasma, allowing water and solutes, like sodium ions, to pass through capillary walls into Bowman's capsule. The filtrate then flows through various...
679
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
422
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
422
Antihypertensive Drugs: Thiazide-Class Diuretics
620
Thiazide diuretics are sulfonamide derivatives featuring a benzothiadiazine ring system in their molecular structure. Based on this structure, thiazide diuretics can be categorized into two groups: thiazide-type and thiazide-like diuretics. Thiazide-type diuretics, including hydrochlorothiazide and chlorothiazide, consist of a benzothiadiazine backbone with an attached sulfonamide group. Thiazide-like diuretics, such as chlorthalidone and indapamide, lack the thiazide ring but demonstrate...
620
Heart Failure Drugs: β-Blockers
337
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
337


